Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB6Q19)

• Drug Name: AMG 820 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMB6Q19

Molecule-Related Drug Atlas

Drug(s) Targeting Colony stimulating factor-1 receptor (CSF-1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARRY-382	DM0VGDC	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
RG7155	DM8JMNL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
MCS-110	DM0CL4I	Bone metastases	2D50	Phase 2	[2]
JNJ-40346527	DM219SF	Hodgkin lymphoma	2B30	Phase 2	[6]
PD-360324	DM6F5EV	Rheumatoid arthritis	FA20	Phase 2	[7]
FPA-008	DM3ZN6Y	Autoimmune diabetes	5A10	Phase 1/2	[8]
IMC-CS4	DMUYN26	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

Drug(s) Targeting Granulocyte colony-stimulating factor receptor (G-CSF-R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tbo-Filgrastim	DML6OE7	Neutropenia	4B00.0	Approved	[9]
Pegfilgrastim	DM7UP8X	Central nervous system neoplasm		Approved	[10]
Peg-G-CSF	DMBKWAF	Solid tumour/cancer	2A00-2F9Z	Phase 3	[11]
BLZ-945	DMG1LVA	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[11]
SBC-014	DMG1VXR	Neutropenia	4B00.0	Phase 2	[12]
AX-200	DMTAEMB	Cardiovascular disease	BA00-BE2Z	Phase 2	[13]
MAXY-G34	DMWLIPJ	Neutropenia	4B00.0	Phase 2	[14]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[15]
MK-6302	DMZUA5C	Neutropenia	4B00.0	Phase 1	[16]
PLX-5622	DMK4PWM	Autoimmune diabetes	5A10	Phase 1	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Colony stimulating factor-1 receptor (CSF-1R)	TT731LW	E9PEK4_HUMAN	Modulator	[2]
Granulocyte colony-stimulating factor receptor (G-CSF-R)	TTC70AJ	CSF3R_HUMAN	Inhibitor	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031593)
• [2] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Company report (Array)
• [5] Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59.
• [6] An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50.
• [7] Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.Clin Exp Immunol.2016 Feb;183(2):258-70.
• [8] Company report (Five Prime Therapeutics)
• [9] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [10] Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
• [12] A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9: 2.
• [13] Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke. 2013 Oct;44(10):2681-7.
• [14] Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 2014 Jan;106(1):21-38.
• [15] National Cancer Institute Drug Dictionary (drug id 747694).
• [16] Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636.
• [17] Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Mol Med. 2012; 18(1): 519-527.